THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 64 filers reported holding THESEUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,169 | -70.1% | 10,100 | +3.7% | 0.00% | -100.0% |
| Q2 2023 | $90,884 | +24.8% | 9,741 | +18.8% | 0.00% | – |
| Q1 2023 | $72,825 | +82.0% | 8,201 | +2.0% | 0.00% | – |
| Q4 2022 | $40,024 | -14.8% | 8,037 | -0.4% | 0.00% | – |
| Q3 2022 | $47,000 | +6.8% | 8,066 | +1.4% | 0.00% | – |
| Q2 2022 | $44,000 | -33.3% | 7,952 | +39.2% | 0.00% | – |
| Q1 2022 | $66,000 | -15.4% | 5,714 | -6.6% | 0.00% | – |
| Q4 2021 | $78,000 | – | 6,116 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 4,108,796 | $11,052,661 | 17.63% |
| Omega Fund Management, LLC | 711,479 | $1,913,879 | 1.76% |
| Lynx1 Capital Management LP | 702,415 | $1,889,496 | 1.25% |
| Orbimed Advisors | 17,713,600 | $47,649,584 | 1.01% |
| Nextech Invest Ltd. | 611,310 | $1,644,424 | 0.50% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $6,047,642 | 0.40% |
| Affinity Asset Advisors, LLC | 400,726 | $1,077,953 | 0.30% |
| DENALI ADVISORS LLC | 127,900 | $344,051 | 0.12% |
| Rock Springs Capital Management LP | 437,329 | $1,176,415 | 0.03% |
| Forefront Analytics, LLC | 17,672 | $47,539 | 0.03% |